Избирательная элиминация клеточных популяций конъюгатами на основе трансферрина человека и растительных токсинов

Список литературы

1. Халанский А.С., Кондакова Л. И., Авцын А.П.// Новые перевиваемые глиомы головного мозга крыс. // Вопросы нейрохирургии. N2, 1995, стр. 2325.
2. Aisen Р, Wessling-Resnick М, Leibold Е. //Iron metabolizm. //Curr Opinion in Chem Biol 1999, 3:200−206
3. Argent P, Roberts LM, Wales R, Robertus JD, Lord JM.// Intriduction of a disulfide bond into ricin A-chain decreases the cytotoxicity of the ricin holotoxin.//J Biol Chem 1994, 269:26 705−10
4. Azzam HS, Grinberg A, Lui K, Shen H, Shores EW, Love PE. // CD5 expression is developmentally regulated by T cell receptor (TCR) avidity. // J Exp Med 1998, 188:2301−11
5. Bailey S, Evans RW, Garratt RC, Gorinsky B, Hasnain S, Horaburgh C, Jhoti H, Lindley PF, Mydin A, Sarra R, Watson JL. // Molecular structure of serum transferrin at 3,3A resolution.// Biochemistry 1988, 27:5804−12
6. Baluna R, Rizo J, Gordon BE, Ghetie V, Vitetta ES. // Evidence for a structural motif in toxins and interleukin-2 that may be responsible for binding to endothelial cells and initiating vascular leak syndrome.// Proc Natl Acad Sci USA 1999,96:3957−62
7. Baluna R, Vitetta ES. // Vascular leak syndrome: a side effect of immunotherapy.//Immunopharmacology 1997, 37(2−3): 117−32
8. Bernstein JJ, Woodard CA. // Glioblastoma cells do not intravasate into blood vessels.//Neurosurgery 1995, 36:124−32
9. Beyers AD, Spruyt LL, Williams AF. // Molecular assotiations between the T-lymphocyte antigen receptor complex and the surface antigens CD2, CD4, or CD8 and CD5.// Proc. Natl. Acad. Sci. USA, 1992, 89:2945−49
10. Biancone L, Bowen MA, Lim A, Aruffo A, Andes G, Stamencovic I. //Identification of a novel inducible cell-surface ligand of CD5 on activated lymphocytes.// J Exp Med 1996, 184:811−819
11. Bilge A, Warner C, Press O. // Translocation of ricin A-chain into proteoliposomes reconstituted from Golgi and endoplasmic reticulum // J Biol Chem 1995, 270:23 720−25
12. Bradbury MW// Transport of iron in the blood-brain-cerebrospinal fluid system// J Neurochem 1997, 69(2):443−54
13. Burrows FJ, Watanabe Y, Thorpe PE. // A murine model for antibody-directed targeting of vascular endothelial cells in solid tumors.// Cancer Res 1992, 52:5954−62
14. Cavallaro U, Nykjaer A, Nielsen M, Soria MR. // Alpha 2-macroglobulin receptor mediates binding and cytotoxicity of plant ribisome-inactivating proteins.// Eur J Biochem 1995,232:165
15. Carayon P, Bord A, Gaillard J. P//Ricin A-chain cytotoxicity depends on its presentation to the cell membrane// Bioconjgate Chem., 1993,4:146−152
16. Cazzola M, Bergamaschi G, Dezza L, D’Uva R, Rosti V, Ascari E. //Cytotoxic activity of an anti-transferrin receptor immunotoxin on normal and leukemic human hematopoietic progenitors.// Cancer Res 1991, 51(2):536−41
17. Chintala SK, Gokaslan ZL, Go Y, Sawaya R, Nicolson GL, Rao JS. // Role of extracellular matrix proteins in regulation of human glioma cell invasion in vitro.// Clin Exp Metastasis 1996, 14:358−66
18. Chignola R, Anselmi A, Franceschi A, Pasti M, Candiani C, TridenteG, Colombatti M. // Sensitivity of human leukemia cells in exponential orstationary growth phase to anti-CD5 immunotoxins.// J Immunol 1994, 152:2333−2343
19. Colombatti M, Bisconti M, Dell’Arciprete L, Gerosa MA, Tridente G. // Sensitivity of human glioma cells to cytotoxic heteroconjugates.// Int J Cancer 1988, 42(3):441−48
20. Colombatti M, Dell’Arciprete L, Chignola R, Tridente G. // Carrier protein-monensin conjugates: enhancement of immunotoxin cytotoxicity and potential in tumor treatment.// Cancer Res 1990, 50(5):1385−91
21. Collawn J.F., Stangel M., Kuhn L.A. // Trasferrin Receptor internalizaion sequence YXRF implicates a tight turh at the structrural recognition motif for endocytosis//Cell 1990, 63:1061−72
22. DAlessandro AM, D’Andrea G, Di Ciccio L, Brisdelli F, Rinaldi AC, Bozzi A, Oratore A. //3'-azido-3'-deoxythymidine reduces the rate of transferrin receptor endocytosis in K562 cells.// BBA 1999, 1450, p.232−41
23. Eguchi Y., Shimizu S. and Tsujimoto Y. //Intracellular ATP levels determine cell death fate by apoptosis or necrosis, Cancer Res 1997,57:1835−40.
24. Endo Y, Mitsui K, Tsurugi K. // The mechanism of action of ricin and related toxic lectins on eukaryotic ribosomes.// J Biol Chem 1987,262:5908−12
25. Endo Y, Tsurugi K, Lambert JM. //The site of action of six different ribosome-inactivating proteins from plants on eukariotic ribosomes: the RNA Nglycosidase activity of the proteins.// Biocem Biophys Res Commun 1988, 150:1032−36
26. Falini B, Terenzi A, Liso A, Flenghi L, Solinas A, Pasqualucci L. // Targeted antibodies in the treatment of lymphomas.// Cancer Surv 1997,30:295−309
27. Fishman JB, Rubin JB, Handrahan JV, Connor JR, Fine RE. //Receptor-mediated transcytosis of transferrin across the blood-brain barrier.// J Neurosci Res 1987, 18:2, p.299−304
28. Frankel AE, FitzGerald D, SiegallC, Press OW. //Advances in immunotoxin biology and therapy: a summary of the Fourth International Symposyum on immunotoxin. //Cancer Res 1996, 56, p.926−932
29. Franz H. // Viscaceae lectins.// In: Franz H. (ed.) Advances in lectin researh, Berlin, YEB, Verlag volk und Gesundheit, 1989,2:28−59
30. Freedman RB, Bulleid NJ, Hawkins HS, Paver JL. // Role of protein disulphide-isomerase in the expression of native proteins.// Biochem Soc Symp 1989,55:167−92
31. Fuller SD, Simons K. // Transferrin receptor polarity and recycling accuracy in «tight» and «leaky» strains of madine-darby canine kidney cells.// J Cell Biol 1986,103:1767−79
32. Gadina M, Newton DL, Rybak SM, Wu Y-N, Youle RJ. // Humanized immunotoxins.//Therap Immunol 1994, 1:59−64
33. Ghetie MA, Vitetta ES.// Recent developments in immunotoxin therapy. Current opinion in immunology.// 1994, 6:707−714
34. Ghosh RN, Mallet WG, Soe TT, McGraw ТЕ, Maxfield FR. // An endocytosed TGN38 chimeric protein is delivered to the TGN after trafficking through the endocytic recycling compartment in CHO cells. J Cell Biol 1998, 142(4):923−36
35. Gluck A, Endo Y, Wool I. // The ribosomal RNA identity elements for ricin and for alpha-sarcin: mutations in the putative CG pair that close a GAGA tetraloop.// Nucleic Acids Res 1994, 22:321−24
36. Goldbrunner RH, Bernstein JJ, Tonn J-C. //ECM-mediated glioma cell invasion. // Mycroscopy researh and technique 1998, 43:250−257
37. Goldstein JL, Brown MS, Anderson GW.// Receptor-mediated endocytosis: concepts emerging from the LDL receptor systems.// Ann Rev Cell Biol 1985, 1:1−39
38. Griffin TW, Raso V. //Monensin in lipid emulsion for the potentiation of ricin A-chain immunotoxins.// Cancer Res 1991, 51:16, p. 4316−22
39. Griffin TW, StoclM, Collins J, Fernandes J, Maher VE. //Combined antitumor therapy with chemotherapeutic drug doxorubicin and an anti-transferrin receptor immunotoxin: in vitro and in vivo studies. //J Immunother 1992,11:1,р.12−18
40. Guidos C, Weissman IL. //Sequential occurrence of positive and negative selection during T lymphocyte maturation.// In Molecular mechanisms of immunological recognition. Academic Press, London. 137−147
41. Hage EI, Chahine J-M, Pakdaman R. // Transferrin, a mechanisms for iron release.// Eur J Biochem 1995, 230:1102−10
42. Halling КС, Hailing AC, Murray EM, Ladin BF, Houston LL, Weaver R. // Genomic cloning and characterization of a ricin gene from Ricinus communis.// Nucl Acids Res 1985, 13:8013−33
43. Hansen SH, Sandvig K, van Deurs B. // Molecules internalized by clatrin-independent endocytosis are delivered to endosomes containing transferrin receptors.//J Cell Biol 1993,123(l):89−97
44. Hayes GR, Williams AM, Lucas JJ, Enns CA. // Structure of human transferrin receptor oligosaccharides: conservation of site-specific processing.// Biochemistry 1997, 36:5276−84
45. Hertler AA, Schlossman DM, Borowitz MJ, Blythman HE, Casellas P, Frankel AE. // An anti-CD5 immunotoxin for chronic lymphocytic leukemia: enhancement of cytotoxicity with human serum albumin-monensin.// Int J Cancer 1989,43(2):215−19
46. Hincha DK, Pfuller U, Schmitt JM. // The concentration of cryoprotective lectins in misletoe (Viscum album L.) leaves is correlated with leaf frost hadriness.// Planta 1997,203:140−44
47. Hwang C, Sinskey AJ, Lodish HF. // Oxidized redox state of glutathione in the endoplasmic reticulum.// Science 1992,257:1496−1502
48. Jaffrezou JP, Sikic BI, Laurent G. // Cyclosporin A and cyclosporin SDZ PSC 833 enhance anti-CD5 ricin A-chain immunotoxins in human leukemic T cell.// Blood 1994, 83(2):482−89
49. Jain RK. // Delivery of novel therapeutic agents in tumors: Physiological barrier and strategies.// J Natl Cancer Inst 1989,81:570−76
50. Jefferies WA, Brandon MR, Williams AF, Hunt SV. //Analysis of lumphopoetic stem cells with a monoclonal antibody to the rat transferrin receptor.// Immunology 1985, 54:333−41
51. Johannes L., Tenza D., Antony C. // Retrograde transport of KDEL-bearing B-fragment of Shiga-toxin// J Biol Chem 1997, 272:19 554−61
52. Kim S, Ponka P.// Control of transferring receptor expression via nitric oxide-mediated modulation of iron-regulatory protein 2.//J Biol Chem 1999, 274(46):33 035−42
53. Kimihiko M., Honami Y., Hirofumi K., Bunzo M., Masaaki H. // Alternative structural state of transferrin.// J Biol Chem 1999, 274:10 190−10 194
54. Kreitman RJ.// Immunotoxin in cancer therapy. //Current opinion in immunology. 1999,11:570−78
55. Lamb FI, Roberts LM, Lord JM. //Nucleotide sequence of cloned cDNA coding for preproricin.// Eur J Biochem 1985, 148:265−70
56. Laske DW, Youle RJ, Oldfield EH.// Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors.// Nature Medicine 1997b, 3:12, p.1362−68
57. Lenartz D, Andermahr J, Plum G, Menzel J, Beuth J. //Efficiency of treatment with galactoside-specific lectin from Misletoe against rat glioma.// Anticancer Res 1998, 18:1011−14
58. Lewis MS, Youle RJ. // Ricin subunit assotiation. Thermodynamics and role of the disulfide bond in toxicity.// J Biol Chem 1986,261:11 571−77
59. Lindstrom AL, Erlandsen SL, Kersey JH, Pennell CA. // An in vitro model for toxin-mediated vascular leak syndrome: ricin toxin A chain increases the permeability of human endothelial cell monolayers.//Blood 1997, 90(6):2323−34
60. Llorente A, Rapak A, Schmid SL, van Deurs B, Sandvig K. // Expression of mutant dynamin inhibits toxicity and transport of endocytosed ricin to the Golgi apparatus.// J Cell Biol 1998, 140(3):553−63
61. Llorente A, van Dews B, Sandvig K. // Transport of apically but not basolaterally internalized ricin to the Golgi apparatus is stimulated by 8-Br-cAMP in MDCK cells.// FEBS Lett 1998, 431(2):200−4
62. Lord J, Roberts L, Robertus J. // Ricin: structure, mode of action some current application.//FASEB J 1994, 8:201−8
63. Lord J.M., Roberts L.M. // The intracellular transport of ricin: why mammalian cells are killed and how Ricinus cells servive.// Plant Physiol Biochem 1996, 34(2):253−61
64. Lord J.M., Roberts L.M. //Retrograde transport: going against the flow// Curr. Biol. 1998, 8: R56-R58
65. Madan S, Vasandani VM, Ghosh PC. // Potentiation of ricin cytotoxicity by liposomal monensin under in vitro and in vivo conditions.// Indian J Biochem Biophys 1993, 30(6):405−10
66. Majoul IV, Bastianes PL, Soiling HD. // Transport of an external Lys-Asp-Glu-Leu (KDEL) protein from the plasma membrane to the endoplasmic reticulum: studies with cholera toxin in Vero cells.// J Cell Biol 1996, 133:77 789
67. Meisenbock G, Rothman JE. // The capacity to retrieve escaped ER proteins extends to the trans-most cisternae of the Golgi stack.// J Cell Biol 1995, 129:309−19
68. Mellman I. // Endocytosis and molecular sorting.// Ann Rev Cell Dev Biol 1996,12:575−625
69. Midoux P, Roche AC, Monsigny M.// Quantitation of the binding, uptake, and degradation of fluorescienated neoglycoproteins by flow cytometry. // Cytometry 1987, 8:327−31
70. Moestrup SK, Gliemann J, Pallesen G. // Distribution of the ct2 -macroglobulin receptor/low density lipoprotein receptor-related protein in human tissues.// Cell Tissue Res 1992,269:375
71. Montfort W, Villifranca JE, Monzigo AF, Ernst S, Katzin B, Rutenber E, Xuong NH, Hamlin R, Robertus JD. // The three-dimensoinal structure of ricin at 2,8 A.// J Biolo Chem 1987, 262:5398−403
72. Moos T, Morgan EH // Transferrin and transferrin receptor function in brain barrier systems.// Cell Mol Neurobiol 2000,20(l):77−95
73. Novak U, Kaye AH. // Brain tumour invasion: many cooks can spoil the broth.//Annual Clin Neuroscience 1999, 6(6), 455−463
74. Nunez MT, Glass J. // Iron uptake in reticulocytes/ Inhibition mediated by the ionophores monensin and nigerisin.// J Biol Chem 1985,260(27): 14 707−11
75. Pelham HR, Roberts L.M., Lord J. M // Toxin entry: how reversible is the secretory patway?// Trends Cell Biol 1992,2:183−85
76. Posch M, Sutterluety H, Skern T, Sieser C. //Characterization of the translation-dependent step during iron-regulated decay of transferrin receptor mRNA.// J Biol Chem 1999, 274(23):16 611−18
77. Ramakrishnan S, Bjorn M, Houston L. // Recombinant ricin A-chain conjugated to monoclonal antibodies: improved tumor cell inhibition in the presence of lysosomotropic compounds.//Cancer Res 1989,49:-612−17
78. Rapak A, Falnes P, Olsnes S. // Retrograde transport of mutant ricin to the endoplasmic reticulum with subsequent translocation ti cytosol.// Proc Natl Acad Sci USA 1997, 94:3783−88
79. Raso V, Basala M. // A highly cytotoxic human transferrin-ricin A chain conjugate used to select receptor-modified cells.// J Biol Chem 1984, 259(2): 1143−49
80. Ravel S, Colombatti M, Casellas P. // Internalization and intracellular fate of anti-CD5 monoclonal antibody and anti-CD5 ricin A-chain immunotoxin in human leukemic T cells.// Blood 1992, 79:1511−17
81. Sharon N. // Lectin-carbohydrate complexes of plants and animals: an atomic view.//TIBS, 1993, 18:221−26
82. Simpson JC, Roberts, Lord JM.// Free ricin A-chain reaches an early compartment of the secretory pathway before it enters the cytosol.// Exp Cell Res 1996,229:447−51
83. Soler-Rodriguez AM, Ghetie MA, Oppenheimer-Marks N, Uhr JW, Vitetta ES.// Ricin A-chain and ricin A-chain immunotoxins rapidly damage human endothelial cells: implications for vascular leak syndrome.// Exp Cell Res 1993, 206(2):227−34
84. Spertini F, Stohl W, Ramesh N, Moody C, Geha RS. // Induction of human T cell proliferation by a monoclonal antibody to CD5.// J Immunol 1991, 146:47−52
85. Steinlein LM, Ligman CM, Kessler S, Ikeda RA. // Iron release is reduced by mutations of lysines 206 and 296 in recombinant N-terminal half-transferrin.// Biochemistry 1998,37:13 696−703
86. Sweeney EC, Palmer RA, Pfuller U. // Crystallisation of ribosome inactivating protein MLI from Viscum album (Misletoe) complexed with p-D-galactose.// J Mol Biol 1993,234:1279−81
87. Tacchini L., Bianchi L., Bernelli-Zazzera A., Cairo G. // Transferrin receptor induction by hypoxia.// J Biol Chem 1999,274:24 142−46
88. Thrush GR, Lark LR, Clinchy ВС, Vitetta ES.// Immunotoxins: an update.// Ann Rev Immunol 1996,14, p. 49−71
89. Того M, Cerbon J, Arzt E, Alergia G, Alva R, Meas Y, Estrada OS.// Formation of ion translocating oligomers by nigericin.// J Memb Biol 1987, 95:1−8
90. Trowbridge IS, Domingo DL. // Anti-transferrin receptor monoclonal antibody and toxin-antibody conjugates affect growth of human tumor cells.// Nature 1981,294:171−73
91. Valtonen S, Timonen U, Toivanen P, Kalino H, Kivipelto L, Heiskanen O, Unsgaard G, Kuurne T. // Interstitial chemotherapy with Carmustine-loaded polymers for high-grade gliomas: A randomized double-blind study.// Neurosurg 1997,41:44−48
92. Van De Helde H, Von Hoegen I, Luo W, Parnes JR, Thielemans K. // The B-cell surface protein CD72/Lyb2 is the ligand for CD5. // Nature 1991, 351:662−665
93. Van Deurs B, Sandvig K, Petersen OW, Olsnes S Simons K, Griffits G. // Estimation of the amount of internalized ricin that reaches the trans-Goldgi network.//J Cell Biol 1988, 106:253−67
94. Van Deurs В, Sandvig К, Petersen OW. // The ways of endocytosis.// Int Rev Cytol 1989, 117:131−77
95. Venkatesh YP and Lambert JM. // Galactose-induced dimerization of blocked ricin at acidic pH: evidence for a third galactose-binding site in ricin B-chain.// Glycobiology 1997, 7(3):329−35
96. Vitetta ES, Fulton RJ, May RD, Till M, Uhr JW. // Redesigning nature’s poisons to create anti-tumor reagents.// Science 1987, 238:1098−104
97. Vitetta ES, Thorpe PE, Uhr JW.// Immunotoxins: magic bullets or misguided missiles? //Immunology Today 1993,14:6, p.252−59
98. Wales R, Richardson PT, Roberts LM. // Mutational analysis of the galactose binding ability of recombinant ricin В chain.// J Biol Chem 1991, 266:19 172−79
99. Weston S, Tucker A, Thatcher D, Derbyshire D, Pauptit R. // X-ray structure of recombinant ricin A-chain at 1,8 A resolution.// J Mol Biol 1994,244:410−22
100. Wu AM, Lin S, Chin L, Chow L, Lin J. // Defining the carbohydrate specificities of Abrus precatorius agglutinin as T Gal (l-3)GalNAc.>I/H[Gal (l-3GlcNAc]. // J Biol Chem 1992,267:19 130−39
101. Wu YN, Gadina M, Tao-Cheng JH, Youle RJ.// Retinoic acid distrupts the Golgi apparatus and increases the cytosolic routing of specific protein toxins. // J Cell Biol 1994, 125(4):743−53
102. Wu M.// Enhancement of immunotoxin activity using chemical and biological reagents.// Br J Cancer 1997, 75(9): 1347−55
103. Yazdi PT, Wenning LA, Murphy RM. // Influence of cellular trafficking on protein synthesis inhibition of immunotoxins directed against the transferrin receptor.//Cancer Res 1995, 55(17):3763−71